Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
61,230.04 -3,079.46 (-4.79%) CMC Crypto 200
1,262.22 -47.50 (-3.63%)
BNGO Jan 2025 1.000 call
| Previous close | 0.2500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1000 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.15k |
GlobeNewswireBionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflowVIA is expected to enhance Revvity’s newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow’s interpretation capabilities SAN DIEGO, June 20, 2024 (G
GlobeNewswireBionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in
- GlobeNewswire
Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applicationsBionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM workflow delivered by Bionano’s chief medical officer, Dr. Alka C
